Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity
about
Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic PeptidesPoor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptideThe structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexesClass I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contactsT cell activity correlates with oligomeric peptide-major histocompatibility complex binding on T cell surfaceProline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptidesIdentification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positionsProtection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.Strategies for designing and optimizing new generation vaccines.Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M.EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutationDifferential phenotypic and functional profiles of TcCA-2 -specific cytotoxic CD8+ T cells in the asymptomatic versus cardiac phase in Chagasic patients.Progress on new vaccine strategies against chronic viral infectionsCross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians.High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligandReverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles.Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequenceFactors influencing immunodominance hierarchies in TCD8+ -mediated antiviral responses.Novel approaches in polyepitope T-cell vaccine development against HIV-1.A cell-based MHC stabilization assay for the detection of peptide binding to the canine classical class I molecule, DLA-88CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells.Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity.Pan-Specific Prediction of Peptide-MHC Class I Complex Stability, a Correlate of T Cell ImmunogenicityModulation of the strength and character of HIV-specific CD8+ T cell responses with heteroclitic peptides.Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals.Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.The lifespan of major histocompatibility complex class I/peptide complexes determines the efficiency of cytotoxic T-lymphocyte responses.Peptide binding by class I and class II MHC molecules.Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice.Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope.Binding of viral antigens to major histocompatibility complex class I H-2Db molecules is controlled by dominant negative elements at peptide non-anchor residues. Implications for peptide selection and presentation.
P2860
Q26800123-90F33657-233C-4F4A-A4DD-C07F395922F2Q27620636-9BFFAF4E-20F5-4BD5-8C5F-A77D489F2C08Q27620750-D7E8783F-75CD-4B49-B8BF-9BFABA1C0150Q27631018-4F959379-9529-4569-B303-7FC581659D98Q27635182-1FBF7F20-064F-4295-8DEF-8C87DBA2BC2AQ27685375-DD72C7EF-1CBA-4C9E-9DB7-5F8025AA8C1AQ30418879-CF55ABB0-2771-473B-ACB3-4587C8EF36E9Q30448796-762EB258-76D7-40DF-A4A5-51FF51A5FE30Q30449492-D5C909D6-1614-48DC-9CB3-A6581B297797Q34004266-C92D69DA-123F-47AF-A007-C8AFD0D61097Q34572198-EFAD945B-FD6F-4123-9E27-6C95CA3FA441Q34981322-6E2A2377-694C-4F17-8861-88D18D3F6A73Q35040888-16C96BBE-77FA-4F94-8762-FD4F3A943E71Q35588670-9E745B29-B9FB-486E-9935-C930CDB02F80Q35864857-404356FE-8CA5-4E33-90E6-7FA6C3C9273AQ35899325-D2026726-125C-4BAC-9068-A18BCDD20570Q36043015-AF9501E4-CD86-4CEC-8347-07A7E383239AQ36401461-3563393F-7C81-47A1-9FB3-3AB78CF87A75Q36471831-0DC47144-8A7C-420C-BA72-21283A2C158DQ36597984-67708E9F-378A-4B96-936E-99EB20748B71Q37754754-BC128D0D-F144-49F7-9997-CA3DFF68CB9BQ38168900-47ED5D1A-9362-4817-B146-FE2151A954B2Q39260317-2CBA6092-BB13-4FBE-9DE6-90CD87D62B3FQ39533424-EADD159B-65AC-4E8B-90F6-2FFE080E9DBBQ39606015-FEAC2332-3167-451E-9900-F32094128FF9Q39611616-5754A558-F203-4B2D-818C-C001B40CD59CQ40047262-36A2CF37-DFE8-4F53-A893-00631DBAAF96Q40761226-DF166807-F334-4ECB-BB96-950D8564F0DAQ40933846-6EF3D014-CC12-498A-9EE2-EE22A7D71BABQ40955850-C5CD74A6-5ABC-4391-A46F-3948036DCD35Q41605278-1E2D4EEE-787E-418D-B9FA-C027FE16441FQ43760325-D39C78D9-0E0C-49B7-A315-10435DF94191Q44020572-94146104-1C19-4228-9B33-68E98779F9E4Q44923807-60110A49-9899-4F3E-A413-C1FFE99D2776
P2860
Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity
description
1995 nî lūn-bûn
@nan
1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Amino-terminal alteration of t ...... ty and in vitro immunogenicity
@ast
Amino-terminal alteration of t ...... ty and in vitro immunogenicity
@en
type
label
Amino-terminal alteration of t ...... ty and in vitro immunogenicity
@ast
Amino-terminal alteration of t ...... ty and in vitro immunogenicity
@en
prefLabel
Amino-terminal alteration of t ...... ty and in vitro immunogenicity
@ast
Amino-terminal alteration of t ...... ty and in vitro immunogenicity
@en
P2093
P2860
P356
P1476
Amino-terminal alteration of t ...... ty and in vitro immunogenicity
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.18.8166
P407
P577
1995-08-01T00:00:00Z